Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Foghorn Therapeutics Inc FHTX

Healthcare Biotechnology
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies... see more

Recent & Breaking News (NDAQ:FHTX)

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

GlobeNewswire 2 days ago

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire November 25, 2025

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

GlobeNewswire November 5, 2025

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire November 3, 2025

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

GlobeNewswire October 30, 2025

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

GlobeNewswire October 16, 2025

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire August 27, 2025

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

GlobeNewswire August 5, 2025

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

GlobeNewswire May 22, 2025

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

GlobeNewswire May 14, 2025

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

GlobeNewswire May 5, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

GlobeNewswire May 1, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

GlobeNewswire April 28, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

GlobeNewswire April 15, 2025

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

GlobeNewswire March 25, 2025

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

GlobeNewswire March 6, 2025

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire February 25, 2025

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

GlobeNewswire January 13, 2025

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

GlobeNewswire December 16, 2024

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire November 12, 2024

Podcasts